Lilly Brings FDA-Approved GLP-1 Treatments to Hims & Hers Digital Platform
November 9, 2026
<p>Eli Lilly has partnered with digital health platform Hims & Hers Health to expand patient access to its FDA-approved obesity treatments, Zepbound (tirzepatide) and Foundayo (orforglipron). The agreement allows eligible patients to access these medicines through the Hims & Hers platform at Lilly's existing self-pay prices.</p><p>The partnership combines Lilly's obesity treatment portfolio with Hims & Hers' digital healthcare services. Patients can consult licensed healthcare providers online, receive a prescription when clinically appropriate, and have their prescribed medication delivered directly to their homes.</p><p>Under the agreement, monthly self-pay prices start at <strong>$149 for Foundayo</strong> and <strong>$299 for Zepbound</strong>. Patients can access these prices through the Hims & Hers platform without needing to move to another service to complete their purchase.</p><p>The agreement reflects the growing role of telehealth in obesity treatment. <a href="https://www.towardshealthcare.com/insights/digital-health-market-is-key-to-a-healthier-future">Digital healthcare platforms</a> allow patients to connect with providers remotely, discuss treatment options and receive ongoing care without depending entirely on traditional in-person consultations.</p><p>For people managing obesity, access involves more than obtaining medication. They may also need clinical guidance, regular monitoring, nutritional support and adjustments to their treatment plans. Hims & Hers offers a membership-based care experience that includes 24/7 access to its care team, nutrition guidance, clinical check-ins and a weight-loss community.</p><p>For Lilly, the partnership creates another channel to connect its FDA-approved obesity medicines with patients seeking digital healthcare services. Foundayo, its daily <a href="https://www.towardshealthcare.com/insights/oral-glp-1-market-sizing">oral GLP-1 medicine</a>, adds an option for patients who prefer an oral treatment, while Zepbound provides an injectable treatment choice.</p><p>The agreement also establishes clear boundaries around prescribing decisions. Licensed providers on the Hims & Hers platform will independently determine which treatment is appropriate for each patient. The companies have committed to protecting clinical decision-making rather than directing providers toward a particular medicine.</p><p>Another important part of the agreement is the companies' position on compounded medicines. Hims & Hers stated that it has never offered compounded copies of <a href="https://www.towardshealthcare.com/insights/glp1-drugs-market-sizing">Lilly's GLP-1 medicines</a> and has committed not to offer them in the future.</p><p>The collaboration comes as pharmaceutical companies increasingly explore partnerships with digital health platforms to improve patient access and treatment delivery. These arrangements can connect established drug manufacturers with online healthcare networks that provide consultations, prescriptions and follow-up support.</p><p>For Lilly, working with Hims & Hers provides access to an established digital healthcare platform. For Hims & Hers, the agreement expands its treatment offering through access to FDA-approved medicines from a major pharmaceutical manufacturer.</p><p>The partnership could also influence how obesity medicines are distributed and accessed in the United States, particularly among patients who prefer self-pay options and online healthcare services.</p><p align="center" style="text-align:center;"><strong>About Eli Lilly</strong></p><p align="center" style="text-align:center;">Eli Lilly and Company is a global pharmaceutical company developing medicines across diabetes, obesity, oncology, immunology and neuroscience. Its portfolio includes Zepbound, Mounjaro and Foundayo.</p><p align="center" style="text-align:center;"><strong>About Hims & Hers</strong></p><p align="center" style="text-align:center;">Hims & Hers Health is a consumer-focused digital healthcare company providing online access to healthcare professionals, prescription treatments and ongoing care services across several health categories.</p><p align="center" style="text-align:center;"><strong>References:</strong></p><p align="center" style="text-align:center;"><a href="https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines">https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines</a></p><p align="center" style="text-align:center;"><a href="https://www.towardshealthcare.com/">https://www.towardshealthcare.com/</a></p>